Trial reportJournal of clinical psychopharmacology2012
Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women.
Trial report in Journal of clinical psychopharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 6 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Extended-release naltrexone versus oral naltrexone for substance use disorders: A systematic review and meta-analysis.Drug and alcohol dependence · 2025Pooled it
- Multi-ancestry meta-analysis of tobacco use disorder identifies 461 potential risk genes and reveals associations with multiple health outcomes.Nature human behaviour · 2024Pooled it
- A systematic meta-epidemiologic review on nonabstinence-inclusive interventions for substance use: inclusion of race/ethnicity and sex assigned at birth/gender.The American journal of drug and alcohol abuse · 2024Pooled it
- Interventions for preventing weight gain after smoking cessation.The Cochrane database of systematic reviews · 2021Pooled it
- Pooled it
- Opioid antagonists for smoking cessation.The Cochrane database of systematic reviews · 2013Pooled it
- The Effects of Menstrual Cycle Hormones on Responses to Varenicline and Naltrexone Among Female Heavy Drinking Smokers.Alcohol and alcoholism (Oxford, Oxfordshire) · 2022Trial
- Efficacy of Combining Varenicline and Naltrexone for Smoking Cessation and Drinking Reduction: A Randomized Clinical Trial.The American journal of psychiatry · 2021Trial
- Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation and May Reduce Post-Cessation Weight Gain: A Pilot Randomized Controlled Trial.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2021Trial
- Evaluation of a Randomized Clinical Trial Comparing the Effectiveness of a Culturally Targeted and Nontargeted Smoking Cessation Intervention for Lesbian, Gay, Bisexual, and Transgender Smokers.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2019Trial
- Neuroimaging findings from an experimental pharmacology trial of naltrexone in heavy drinkers of East Asian descent.Drug and alcohol dependence · 2019Trial
- Naltrexone and alcohol effects on craving for cigarettes in heavy drinking smokers.Experimental and clinical psychopharmacology · 2019Trial
- A Double-Blind Randomized Placebo-Controlled Trial of Oral Naltrexone for Heavy-Drinking Smokers Seeking Smoking Cessation Treatment.Alcoholism, clinical and experimental research · 2017Trial
- Combined varenicline and naltrexone treatment reduces smoking topography intensity in heavy-drinking smokers.Pharmacology, biochemistry, and behavior · 2015Trial
- Sex differences in acute hormonal and subjective response to naltrexone: The impact of menstrual cycle phase.Psychoneuroendocrinology · 2015Trial
- Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings.The American journal of drug and alcohol abuse · 2015Trial
- Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings.Psychopharmacology · 2014Trial
- Naltrexone improves quit rates, attenuates smoking urge, and reduces alcohol use in heavy drinking smokers attempting to quit smoking.Alcoholism, clinical and experimental research · 2014Trial
- Spontaneous reductions in smoking during double-blind buprenorphine detoxification.Addictive behaviors · 2014Trial
- Effects of the opioid receptor antagonist naltrexone on smoking and related behaviors in smokers preparing to quit: a randomized controlled trial.Addiction (Abingdon, England) · 2013Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
This study examined whether the opioid receptor antagonist naltrexone is efficacious in smoking cessation and whether sex moderates the response. We assessed smoking quit rates and weight gain in a double-blind randomized trial comparing oral naltrexone (n = 162) with placebo (n = 154) in nicotine-dependent participants who wanted to quit smoking. The medication was gradually titrated up to 50 mg during the week before the quit date and then maintained at this dose for 12 weeks. For the first 4 weeks after the quit date, all participants received a nicotine patch to mitigate tobacco withdrawal and attended weekly individual cognitive-behavioral smoking cessation counseling sessions. After this time, participants continued with naltrexone or placebo through 12 weeks. Follow-up assessments were conducted at 26 and 52 weeks. During treatment, naltrexone (vs placebo) increased quit rates, attenuated smoking urge, and reduced weight gain. At follow-up, after medication discontinuation, the effect of naltrexone on improving quit rates was no longer evident. Men and women experienced different benefits from naltrexone; men showed greater reductions in smoking, whereas women showed greater reductions in weight gain. In sum, naltrexone showed acute efficacy in treating nicotine dependence, but after the medication was discontinued, the effect on quit rate was not maintained. Further study of naltrexone in smoking cessation treatment and reduction of cessation-related weight gain, as well as preclinical investigation of mechanisms underlying sex differences, is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.